Details of the Drug

General Information of Drug (ID: DMZGKXW)

Drug Name

Atogepant

Synonyms

UNII-7CRV8RR151; 7CRV8RR151; AGN-241689; MK-8031; 1374248-81-3; Atogepant [INN]; Atogepant [WHO-DD]; Atogepant [USAN:INN]; SCHEMBL4570348; GTPL9730; CHEMBL3991065; example 4 [US20120122911]; Spiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carboxamide, 1',2',5,7-tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)-3-piperidinyl)-2'-oxo-, (3'S)-; (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1

Indication

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Approved	[1]

Affected Organisms

Humans and other mammals

ATC Code

N02CD07: Atogepant

N02CD: Calcitonin gene-related peptide (CGRP) antagonists

N02C: ANTIMIGRAINE PREPARATIONS

N02: ANALGESICS

N: NERVOUS SYSTEM

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

603.5

Logarithm of the Partition Coefficient (xlogp)

3.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2-3 h [2]
Clearance: The apparent oral clearance of drug is 19 L/h [2]
Elimination: Following a single oral dose of radiolabeled atogepant to healthy male subjects, 42% of the administered dose was recovered as unchanged parent drug in the feces and 5% as unchanged parent drug in the urine [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 11 hours [2]
Metabolism: The drug is metabolized via the CYP3A4 [2]
Vd: The volume of distribution (Vd) of drug is 292 L [2]

Chemical Identifiers

Formula: C29H23F6N5O3
IUPAC Name: (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
Canonical SMILES: C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F
InChI: InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1
InChIKey: QIVUCLWGARAQIO-OLIXTKCUSA-N

Cross-matching ID

PubChem CID: 72163100
ChEBI ID: CHEMBL3991065
CAS Number: 1374248-81-3
UNII: 7CRV8RR151
DrugBank ID: DB16098
TTD ID: D02ZUG

Drug-Molecule Activity Atlas (DMA)^NEW

Click to Jump to the Detailed DMA Information of This Drug

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcitonin gene-related peptide receptor (CGRPR)	TTY6O0Q	CALRL_HUMAN	Antagonist	[3]
Calgranulin D (S100A12)	TTQ4ESF	S10AC_HUMAN	Antagonist	[3]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215206.
2	FDA Approved Drug Products: Qulipta (atogepant) tablets for oral use
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)